Rapid CommunicationShort Communication
Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential
Guillaume Margaillan, Michèle Rouleau, Kathrin Klein, John K. Fallon, Patrick Caron, Lyne Villeneuve, Philip C. Smith, Ulrich M. Zanger and Chantal Guillemette
Drug Metabolism and Disposition September 2015, 43 (9) 1331-1335; DOI: https://doi.org/10.1124/dmd.115.065391
Guillaume Margaillan
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Michèle Rouleau
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Kathrin Klein
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
John K. Fallon
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Patrick Caron
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Lyne Villeneuve
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Philip C. Smith
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Ulrich M. Zanger
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)
Chantal Guillemette
Pharmacogenomics Laboratory, Centre Hospitalier Universitaire (CHU) de Québec and Faculty of Pharmacy, Université Laval, Québec, Canada (G.M., M.R., P.C., L.V., C.G.); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.K.F., P.C.S.); Canada Research Chair in Pharmacogenomics (C.G.)

DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Rapid CommunicationShort Communication
Quantitative Proteomics Applied to Hepatic Glucuronidation
Guillaume Margaillan, Michèle Rouleau, Kathrin Klein, John K. Fallon, Patrick Caron, Lyne Villeneuve, Philip C. Smith, Ulrich M. Zanger and Chantal Guillemette
Drug Metabolism and Disposition September 1, 2015, 43 (9) 1331-1335; DOI: https://doi.org/10.1124/dmd.115.065391
Rapid CommunicationShort Communication
Quantitative Proteomics Applied to Hepatic Glucuronidation
Guillaume Margaillan, Michèle Rouleau, Kathrin Klein, John K. Fallon, Patrick Caron, Lyne Villeneuve, Philip C. Smith, Ulrich M. Zanger and Chantal Guillemette
Drug Metabolism and Disposition September 1, 2015, 43 (9) 1331-1335; DOI: https://doi.org/10.1124/dmd.115.065391
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement